Z3 Capital Partners’s AbbVie ABBV Stock Holding History

Z3 Capital Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$897K	Sell	3,564 -17	-0.5%	-$3.66K	0.19%	86
2026 Q1	$779K	Buy	3,581 +103	+3%	+$22.8K	0.2%	89
2025 Q4	$795K	Buy	+3,478	New	+$792K	0.19%	88

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Z3 Capital Partners's ABBV Position: Q2 2026 in Review

Z3 Capital Partners reduced its AbbVie (ABBV) stake by 0.47% in Q2 2026, selling an estimated $3.66K and leaving 3,564 shares worth $897K. The position accounts for 0.19% of the portfolio, ranked #86.

Z3 Capital Partners first reported a position in ABBV in Q4 2025 and has held it in 3 quarters since. 4,063 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Z3 Capital Partners held 3,564 shares of AbbVie worth $897K as of Q2 2026.
Z3 Capital Partners sold 17 AbbVie shares in Q2 2026, an estimated $3.66K.
AbbVie made up 0.19% of Z3 Capital Partners's portfolio in Q2 2026, its #86 holding.
Z3 Capital Partners first reported a position in AbbVie in Q4 2025 and has held it in 3 quarters since.
4,063 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Z3 Capital Partners's 13F filing for Q2 2026, filed 28 Jul 2026.